HUP0402179A2 - Poxvírustartalmú készítmények és eljárás stabil, poxvírustartalmú készítmények elõállítására - Google Patents

Poxvírustartalmú készítmények és eljárás stabil, poxvírustartalmú készítmények elõállítására

Info

Publication number
HUP0402179A2
HUP0402179A2 HU0402179A HUP0402179A HUP0402179A2 HU P0402179 A2 HUP0402179 A2 HU P0402179A2 HU 0402179 A HU0402179 A HU 0402179A HU P0402179 A HUP0402179 A HU P0402179A HU P0402179 A2 HUP0402179 A2 HU P0402179A2
Authority
HU
Hungary
Prior art keywords
poxvirus
poxvirus containing
preparation
freeze
preparing stable
Prior art date
Application number
HU0402179A
Other languages
English (en)
Inventor
Paul Howley
Karl Heller
Ingmar Räthe
Original Assignee
Bavarian Nordic A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160885&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0402179(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic A/S filed Critical Bavarian Nordic A/S
Publication of HUP0402179A2 publication Critical patent/HUP0402179A2/hu
Publication of HUP0402179A3 publication Critical patent/HUP0402179A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A találmány tárgya készítmény - előnyösen vizes készítmény -, mely (i)orthopoxvírus, avipoxvírus, parapoxvírus, capripoxvírus vagysuipoxvírusfajok bármelyikéhez tartozó poxvírust, (ii) diszacharidot,(ii) gyógyászatilag elfogadható polimert, adott esetben (iv) pufferttartalmaz. A vizes készítmény különösen alkalmas fagyasztva-szárításoseljárással történő feldolgozásra, melynek eredményeként stabil,fagyasztva-szárított, poxvírus-tartalmú készítményt nyerhető. Atalálmány további tárgya fagyasztva-szárított, poxvírus-tartalmúkészítmény előállítására szolgáló eljárás és az így nyert termék. Ó
HU0402179A 2001-12-10 2002-11-28 Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions HUP0402179A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101831 2001-12-10
PCT/EP2002/013434 WO2003053463A2 (en) 2001-12-10 2002-11-28 Poxvirus-containing compositions and process for their preparation

Publications (2)

Publication Number Publication Date
HUP0402179A2 true HUP0402179A2 (hu) 2005-01-28
HUP0402179A3 HUP0402179A3 (en) 2012-09-28

Family

ID=8160885

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402179A HUP0402179A3 (en) 2001-12-10 2002-11-28 Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions

Country Status (22)

Country Link
US (1) US7094412B2 (hu)
EP (1) EP1418942B1 (hu)
JP (1) JP4439263B2 (hu)
KR (1) KR20040074067A (hu)
CN (1) CN1296096C (hu)
AT (1) ATE300954T1 (hu)
AU (1) AU2002361962A1 (hu)
BR (1) BR0214822A (hu)
CA (1) CA2467365C (hu)
DE (1) DE60205388T2 (hu)
DK (1) DK1418942T3 (hu)
EA (1) EA006880B1 (hu)
ES (1) ES2247414T3 (hu)
HK (1) HK1071295A1 (hu)
HU (1) HUP0402179A3 (hu)
IL (2) IL161590A0 (hu)
MX (1) MXPA04005577A (hu)
NO (1) NO20042958L (hu)
NZ (1) NZ533302A (hu)
PL (1) PL213326B1 (hu)
UA (1) UA78738C2 (hu)
WO (1) WO2003053463A2 (hu)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
CN1692156B (zh) 2002-09-05 2011-05-11 巴法里安诺迪克有限公司 在无血清条件下培养原代细胞和扩增病毒的方法
CN1207005C (zh) 2002-10-31 2005-06-22 威世药业（如皋）有限公司 含生物活性物质的兔皮和其用途
WO2006029467A1 (en) * 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
WO2007056847A1 (en) * 2005-11-21 2007-05-24 Sanofi Pasteur Limited Stabilizing formulations for recombinant viruses
US8012738B2 (en) 2007-05-14 2011-09-06 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
ES2393160T3 (es) * 2007-05-18 2012-12-19 Medimmune, Llc Conservación de materiales bioactivos con espuma liofilizada
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
SG178909A1 (en) 2009-10-08 2012-04-27 Bavarian Nordic As Generation of a broad t-cell response in humans against hiv
KR20130008645A (ko) 2010-05-21 2013-01-22 에이에이치 유에스에이 42 엘엘씨 광견병 바이러스 항원을 함유하는 파라폭스바이러스 벡터
CN103079593A (zh) 2010-07-20 2013-05-01 Ah美国42有限责任公司 副痘病毒载体
AU2011281982B2 (en) 2010-07-20 2015-12-17 Bavarian Nordic A/S Method for harvesting expression products
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
JP6333814B2 (ja) 2012-07-10 2018-05-30 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． マイコバクテリア抗原ワクチン
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
EP3092000A1 (en) 2014-01-09 2016-11-16 Transgene SA Fusion of heterooligomeric mycobacterial antigens
DK3116541T3 (da) 2014-03-12 2020-02-24 Bavarian Nordic As Anvendelse af olie-og-vand-emulsioner til forøgelse af b-celleresponser med modificerede vaccinia-ankara-virus
CA3190510A1 (en) 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
AU2015357225B2 (en) 2014-12-01 2020-04-09 Transgene Sa Stable liquid vaccinia virus formulations
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
TW201825511A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
WO2018122088A1 (en) 2016-12-28 2018-07-05 Transgene Sa Oncolytic viruses and therapeutic molecules
JP7406377B2 (ja) * 2017-05-15 2023-12-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定なウイルス含有組成物
WO2018210804A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2018229711A1 (en) 2017-06-15 2018-12-20 Janssen Vaccines & Prevention B.V. Poxvirus vectors encoding hiv antigens, and methods of use thereof
IL271558B2 (en) 2017-06-21 2024-01-01 Transgene A vaccine tailored to the individual
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
WO2019170820A1 (en) 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
US20210187100A1 (en) 2018-09-06 2021-06-24 Bavarian Nordic A/S Storage Improved Poxvirus Compositions
JPWO2020090871A1 (ja) 2018-10-30 2021-10-07 国立大学法人 東京大学 がん治療のための腫瘍溶解性ウイルス
WO2020136235A1 (en) 2018-12-28 2020-07-02 Transgene Sa M2-defective poxvirus
WO2020136232A1 (en) 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
BR112022017438A2 (pt) 2020-03-12 2022-10-18 Bavarian Nordic As Composições que melhoram a estabilidade do poxvírus
US20230256057A1 (en) 2020-07-13 2023-08-17 Transgene Treatment of immune depression
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2024003239A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
WO2024003238A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S Epstein-barr-virus vaccine
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (hu)
US4380582A (en) * 1965-07-09 1983-04-19 The United States Of America As Represented By The Secretary Of The Army Preparation of dry variola virus
FR7773M (hu) * 1968-06-14 1970-03-23
US3577526A (en) * 1969-06-13 1971-05-04 Merieux Inst Stabilized smallpox vaccine
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
CA2158935A1 (en) * 1993-10-12 1995-04-20 Chiron Viagene, Inc. Methods for preserving recombinant viruses
MY150893A (en) * 1996-09-24 2014-03-14 Bavarian Nordic As Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
GB9808922D0 (en) 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors

Also Published As

Publication number Publication date
HUP0402179A3 (en) 2012-09-28
IL161590A (en) 2009-06-15
EP1418942A2 (en) 2004-05-19
ES2247414T3 (es) 2006-03-01
NO20042958L (no) 2004-07-09
US7094412B2 (en) 2006-08-22
BR0214822A (pt) 2004-12-14
DK1418942T3 (da) 2005-11-28
JP2005513109A (ja) 2005-05-12
EA006880B1 (ru) 2006-04-28
US20050019349A1 (en) 2005-01-27
CN1602205A (zh) 2005-03-30
CA2467365A1 (en) 2003-07-03
MXPA04005577A (es) 2005-04-19
PL369954A1 (en) 2005-05-02
DE60205388D1 (de) 2005-09-08
PL213326B1 (pl) 2013-02-28
ATE300954T1 (de) 2005-08-15
AU2002361962A1 (en) 2003-07-09
UA78738C2 (en) 2007-04-25
KR20040074067A (ko) 2004-08-21
CA2467365C (en) 2012-11-20
CN1296096C (zh) 2007-01-24
IL161590A0 (en) 2004-09-27
EA200400796A1 (ru) 2004-12-30
EP1418942B1 (en) 2005-08-03
HK1071295A1 (en) 2005-07-15
NZ533302A (en) 2005-11-25
JP4439263B2 (ja) 2010-03-24
WO2003053463A3 (en) 2004-03-04
DE60205388T2 (de) 2006-03-30
WO2003053463A2 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
HUP0402179A2 (hu) Poxvírustartalmú készítmények és eljárás stabil, poxvírustartalmú készítmények elõállítására
BRPI0511441B8 (pt) composições contendo uma partícula de glucano oca ou partícula de parede celular encapsulando um componente de terpeno, métodos de fabricação e uso das mesmas
PH12017501898A1 (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
BRPI0515520A (pt) composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
WO2002028422A3 (en) Split enveloped virus preparation for intranasal delivery
NZ707328A (en) Virus-containing formulation and use thereof
BRPI0712158B8 (pt) processo para produzir uma composição de poxvírus de tipo selvagem, atenuado e/ou recombinante sem especificidade de infecção visada
WO2007054279A3 (en) Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
NO20045480L (no) Intergeniske regioner som innskuddsseter i genomet til vacciniavirus ankara(MVA)
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
BR0309339A (pt) Vìrus vaccinia modificado ankara para a vacinação de neonatos
WO2001000232A3 (en) Use of cpg as an adjuvant for hiv vaccine
WO2007059931A8 (en) New adjuvants on the basis of bisacyloxypropylcysteine conjugates and derivatives and their uses in pharmaceutical compositions
WO1996005866A3 (de) Lebendvakzine zur behandlung von tumorerkrankungen
SG11201804192SA (en) Composition for preventing or treating hair loss comprising chemokine (c-x-c motif) ligand 1 (cxcl1) protein
WO2022103929A3 (en) Nucleic acids, proteins, and vaccines of sars-cov-2
WO2018105941A3 (ko) 탈모방지 또는 발모촉진용 주사용 조성물
WO2004084935A3 (en) Francisella strain for live vaccine
PT1682162E (pt) Utilização de opuntia para a produção de um medicamento para o tratamento da depressão
WO2003080112A3 (en) Imidazoquinolineamines as adjuvants in hiv dna vaccination
Boo et al. Comparative antioxidant enzyme activity of diploid and tetraploid Platycodon grandiflorum by different drying methods
MX2021015155A (es) Polisacaridos de ramnosa.
WO2016184577A3 (en) Dry powder composition comprising long-chain rna
MXPA03010053A (es) Vacuna de microplasma inactivada con saponina.
CN106860662A (zh) 一种扁桃体炎治疗药物

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished